The Forever Chemical Regulation and Accountability Act of 2026 (SB 4153) directs EPA to drive the nationwide elimination of nonessential uses of perfluoroalkyl and polyfluoroalkyl substances (PFAS) and to prohibit environmental releases of PFAS. The bill pairs a 10-year phaseout for nonessential uses with interim accelerated bans for specific consumer and industrial product categories, mandatory annual reporting by manufacturers and large users, and a separate EPA rulemaking to set detection methods and a release phaseout schedule.
Beyond use and release limits, the bill establishes a formal National Academies agreement to define “essential uses,” funds regional Centers of Excellence for PFAS detection and remediation research, applies many state and local PFAS laws to federal facilities, preserves citizen-suit enforcement, and inserts a bankruptcy carveout for persistent, bioaccumulative, and toxic (PBT) chemical claims. For compliance officers, product teams, and remediation planners, SB 4153 replaces a patchwork of State action with a single federal architecture that relies heavily on agency rulemaking, data collection, and science-driven designations of essential uses.
At a Glance
What It Does
The bill requires manufacturers and defined users to file annually detailed reports about PFAS identity, volumes, uses, releases, byproducts, disposal, and available safer alternatives; directs EPA to formalize a 10-year program to phase out nonessential PFAS and to ban any environmental release above validated detection thresholds; and creates rulemaking and petition processes to designate essential uses. It also authorizes civil and criminal enforcement, citizen suits, and immediate administrative action for imminent hazards.
Who It Affects
Importers, producers, processors, and users of PFAS (including companies that import products known to contain PFAS), state and local governments involved in remediation, federal procurement offices and agencies that procure goods, National Laboratories and eligible universities chosen for Centers of Excellence, and communities exposed to PFAS contamination.
Why It Matters
SB 4153 shifts U.S. policy from piecemeal regulation to an explicit elimination strategy tied to science-based essential-use designations and nationwide release limits. It creates new transparency obligations, funds remediation research infrastructure, and changes litigation and bankruptcy dynamics for PFAS-related claims — all of which materially affect compliance planning, product portfolios, government procurement, and remediation funding.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
SB 4153 creates a multi-part federal program to end nonessential PFAS uses and to stop PFAS releases into the environment. The bill begins by defining terms (manufacturer, user, essential use, safer alternative) and then directs EPA to sign a decade-long agreement with the National Academies to review uses of PFAS and produce science-based guidance and recurring reports that will inform regulatory designations of essential versus nonessential uses.
Those National Academies reports are expected to set criteria and identify research gaps, and EPA may use them (and subsequent updates) as the basis for designations and rulemaking.
On reporting and phaseout mechanics, EPA must adopt a rule requiring manufacturers and users to file annual reports (content specified in the bill) and must require plans from each firm for phasing out nonessential uses within 10 years. The bill sets accelerated, product-specific sales prohibitions for categories such as carpets, fabric treatments, food packaging, juvenile products, cosmetics, certain textiles, and severe-wet-condition outdoor apparel on 1- to 5-year schedules.
It also authorizes EPA to force more stringent schedules after notice and public comment, and allows petitions and agency rulemaking to designate specific uses as essential or nonessential.SB 4153 imposes a release ban: beginning 10 years after enactment, no manufacturer or user may release any quantity of PFAS above the detection threshold of an EPA-validated method. EPA must complete the detection-method and phaseout rulemaking within seven years (with authority to adopt earlier, substance-specific bans).
The bill also contemplates research exceptions — EPA can permit limited uses or transfers of remaining PFAS stocks to accredited research consortia, National Labs, and Centers of Excellence where such uses directly advance destruction, detection, or remediation capabilities.Enforcement and remedies are broad. EPA may issue compliance orders, assess civil penalties calculated to remove economic benefit from violations, and initiate injunctive actions; criminal penalties apply for reckless violations.
The statute preserves and refines citizen-suit authority (with specified notice periods), instructs EPA on imminent-hazard orders and required community notification, and makes clear that federal facilities must comply with state and local PFAS requirements (subject to a presidential national-security waiver limited to one-year terms). Finally, the bill creates Centers of Excellence (a university–National Lab Center and a rural center) to expand measurement, remediation, and technology-transfer capacity, and it amends CERCLA and bankruptcy-related practice by inserting a provision that PFAS/PBT claims against non-debtors are not automatically stayed by a debtor’s bankruptcy filing.
The Five Things You Need to Know
EPA must enter a 10-year agreement with the National Academies within 60 days to review and recommend which PFAS uses are ‘essential’; the initial review must conclude within 3 years and produce recurring reports every 2 years.
Manufacturers and defined users must submit annual PFAS reports (within 18 months of the EPA rule) detailing chemical identity, volumes, releases at detectable levels, byproducts, disposal methods, exposed workers, and potential safer alternatives.
The bill imposes accelerated sales bans on specific product categories: certain carpets, fabric treatments, food packaging, juvenile products and oil/gas products within 1 year; cosmetics, many indoor textiles and apparel within 2 years; outdoor furnishings within 4 years; and severe-wet-condition outdoor apparel within 5 years.
EPA must, within 7 years, finalize a rule that (1) establishes validated detection methods and thresholds and (2) sets a schedule to phase out releases above those detection thresholds; full prohibition of nonessential uses and release limits takes effect 10 years after enactment.
SB 4153 adds a bankruptcy-safe harbor exception: a debtor’s bankruptcy filing does not automatically stay claims against non-debtor entities arising from exposure to PFAS/PBT chemicals, preserving litigation options for plaintiffs and third-party claimants.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Definitions for scope and actors
This section supplies working definitions used throughout the bill: ‘perfluoroalkyl or polyfluoroalkyl substance’ (PFAS), ‘manufacturer’ (broadly including importers/exporters and processors), ‘user’ (to be defined by EPA with risk-based considerations), ‘essential use’, and ‘safer alternative’. Practically, these definitions expand regulated parties beyond chemical producers to include product importers and firms that knowingly sell PFAS-containing products, while explicitly excluding entities that merely handle PFAS as part of waste or water treatment operations.
National Academies agreement to define essential uses
EPA must seek a 10-year agreement with the National Academies to review and classify PFAS uses as essential or nonessential, prioritize phaseouts, identify research gaps, and recommend R&D to accelerate alternatives. The Academies’ review must integrate authoritative human-health evidence, consider cumulative and environmental impacts, and produce an initial report within three years, followed by biennial updates — a process that EPA must consider when designating uses under later rulemakings or petitions.
Mandatory annual reporting and manufacturer phaseout plans
EPA is required to adopt a rule that compels manufacturers and users to submit annual reports (chemical identities, volumes, releases at detectable levels, byproducts, worker exposures, and safer alternatives). Within three years each firm must also file a phaseout plan to eliminate nonessential PFAS uses within 10 years; EPA will publish reports for public comment and may verify data quality. The reporting regime is the data backbone for identifying priority phaseouts and enforcement targets.
Product-specific accelerated sales prohibitions and petition designation process
The bill sets short-term sales prohibitions for clearly defined product groups on 1- to 5-year timelines (e.g., carpets, food packaging, cosmetics, certain apparel). It also establishes a petition process for stakeholders to seek essential-use designations or rulemakings that EPA must decide using best-available science, with public comment windows and the ability for EPA to initiate its own designation rulemaking. Petition fees and process details are tied to the fee rulemaking in Section 113.
National policy and federal procurement
This section states a national policy favoring remediation to safe levels, prioritizing destruction and disposal of PFAS, and eliminating PFAS in consumer products. It orders federal agencies and procurement offices to, to the maximum extent practicable, eliminate purchases of products known to contain PFAS and allows agencies to pause procurement while safer alternatives are identified — creating a lever to reshape demand for PFAS-containing products.
Release phaseout and detection method rulemaking
SB 4153 makes it unlawful for manufacturers or users to release PFAS above EPA-validated detection thresholds starting 10 years after enactment. EPA must promulgate a rule within 7 years to set detection methods, thresholds, and a schedule to phase out releases; the Agency can also adopt earlier substance- or class-specific bans. This provision ties compliance to analytically validated detection capability and gives EPA a staged implementation window.
Research exceptions, stock transfers, monitoring, and entry
EPA may authorize limited uses and verifiable transfers of remaining PFAS stocks for research (destruction, detection, remediation), but it prohibits producing PFAS solely for research unless necessary. EPA also gains broad monitoring and entry powers: the ability to require monitoring equipment, sampling, records, audits, and on-site access to verify compliance; and to publish data subject to CBI protections.
Enforcement, citizen suits, and imminent-hazard authority
Enforcement tools include compliance orders, financial penalties sized to remove economic benefit, civil actions, and criminal penalties for reckless violations. The statute preserves citizen-suit rights with set notice periods and intervention rules, defines procedures for imminent-hazard orders (including mandatory community notification and public meetings), and requires EPA to consider cumulative impacts and community contamination history when setting penalties and remedies.
Federal-facility application, fees/funds, Centers of Excellence, and bankruptcy provision
Federal facilities are subject to state and local PFAS requirements (with a narrowly drawn presidential national-security exemption). Section 113 requires EPA to conduct a workload analysis and then set annual-report and petition fees via rulemaking, deposit fees into two dedicated Treasury funds for administering reporting and petitions, and allows limited fee waivers (e.g., for public-interest petitioners). Title II establishes two Centers of Excellence (a university–National Lab center and a rural center) to scale up measurement and remediation capabilities. Finally, the bill amends CERCLA-related practice to insert a carveout in bankruptcy: PBT/PFAS claims against non-debtors are not automatically stayed by a debtor’s filing.
This bill is one of many.
Codify tracks hundreds of bills on Environment across all five countries.
Explore Environment in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Communities with PFAS contamination — will receive a statutory mandate for phased elimination, remediation prioritization, imminent-hazard notice requirements, and strengthened citizen-suit standing to seek cleanup and injunctive relief.
- Researchers, universities, and National Laboratories — gain new, dedicated Centers of Excellence, funding windows, and formal pathways to receive PFAS stockpiles for destruction/detection research and to scale promising remediation technologies.
- Public water systems and municipal authorities — benefit from nationwide measurement standards, EPA-validated methods, and a federal remediation policy that prioritizes destruction/disposal, which can reduce regulatory patchwork and clarify long-term remediation expectations.
Who Bears the Cost
- PFAS manufacturers, importers, processors, and product suppliers — must file detailed annual reports, create phaseout plans, pay new reporting/petition fees, comply with product sales prohibitions on strict timelines, and face potential civil and criminal penalties for violations.
- Product manufacturers in textiles, food packaging, cosmetics, juvenile products, and certain oil and gas sectors — face accelerated bans for specific product categories, inventory management challenges, and potential redesign costs to meet phaseout schedules.
- Federal procurement offices and certain federal agencies — face new obligations to eliminate PFAS-containing products, possible supply-chain disruptions, and administrative costs for surveys and procurement pauses; national-security waivers may be needed but are time-limited.
- State and local regulators and courts — while the bill preserves state authority and applies state rules to federal facilities, implementing coordinated enforcement and monitoring may increase workloads and require budgets for sampling and oversight.
Key Issues
The Core Tension
The central dilemma is urgency versus readiness: the bill aims to eliminate PFAS exposures quickly to protect public health, but effective and safe elimination depends on validated detection methods, mature destruction technologies, and economically feasible alternatives — none of which are evenly available across chemicals, products, or regions. Policymakers must decide how fast to force transitions (and at what social cost) while avoiding unintended harms from premature substitutions, insufficient destruction capacity, and uneven burdens on communities and small businesses.
Implementation hinges on several technically challenging and administratively consequential choices. First, the release ban is keyed to ‘‘detection thresholds of EPA-validated methods’’ — yet analytical limits vary by matrix (air, water, soil), by PFAS species, and over time as methods improve.
EPA must choose which methods to validate, the list of analytes, and threshold levels; those choices will directly determine when and how the release ban becomes enforceable and which discharges are actionable. That technical dependency creates regulatory uncertainty for firms until EPA finalizes robust, validated measurement standards.
Second, the bill relies heavily on options that currently lack mature, low-cost end-of-life solutions at commercial scale. While the law prioritizes destruction and disposal rather than containment, large-scale destruction technologies (thermal, hydrodefluorination, advanced oxidation, etc.) are at different readiness levels and carry cost, energy, and secondary-waste trade-offs.
The provisions allowing stock transfers to research consortia and National Labs both accelerate R&D and create tension: transferring stockpiles for study delays removal from commerce and concentrates risk where research is conducted. Finally, the fee structure and petition process present procedural trade-offs: fees that are too high could deter public-interest petitions or skew the petition docket toward well-resourced industry actors, while fees that are too low could underfund EPA’s review capacity.
The statute requires EPA rulemaking on fees but sets default minimums if EPA misses its deadline, which risk creating rigid funding and equity outcomes.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.